← Abivax SA overview

Abivax SA vs Abcellera Biologics: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Abivax SA (ABVX.PA)

Q2 2026
▲3▼1

Abivax Soars on Strong Phase 3 Data, Analyst Upgrade, and $800M Raise

  • Positive Phase 3 Data Drives Stock Surge Abivax reported positive Phase 3 ABTECT Maintenance Part 2 results for obefazimod in refractory ulcerative colitis, showing 37.2% clinical remission and 34.5% endoscopic remission at Week 44. This strong efficacy in hard-to-treat patients boosts confidence in the drug's approvability, pushing the stock up 27%.

    This is the core positive catalyst that directly lifted the stock and improved the drug's outlook.

  • Jefferies Upgrade Eases Safety Concerns Jefferies upgraded Abivax to Buy and raised its price target to $158, citing that updated Phase 3 data alleviated concerns over previously reported malignancy cases. The brokerage believes the safety issue is manageable and not a major regulatory hurdle, reinforcing the investment case.

    This analyst action reflects and amplifies the positive data, providing a second driver for the stock's rise.

  • Upsized $800M Offering Extends Cash Runway Abivax priced an upsized $800 million public offering of ADSs at $125 per share, extending its cash runway into Q2 2029. The funds will support commercialization of obefazimod and clinical development, removing near-term financing risk and enabling the company to execute its strategy.

    This capital raise strengthens the balance sheet and supports future growth, a key positive for the stock.

  • Schall Law Firm Investigation Adds Regulatory Overhang The Schall Law Firm is investigating Abivax for potential securities law violations related to undisclosed malignancy cases in the obefazimod trial. This legal scrutiny could lead to fines or reputational damage, weighing on the stock, though the recent positive data may mitigate the impact.

    This is a negative factor that could pressure the stock, providing a balanced view of risks.

June 2026
▲3▼1

Abivax Soars on Strong Phase 3 Data, Analyst Upgrade, and $800M Raise

  • Positive Phase 3 Data Drives Stock Surge Abivax reported positive Phase 3 ABTECT Maintenance Part 2 results for obefazimod in refractory ulcerative colitis, showing 37.2% clinical remission and 34.5% endoscopic remission at Week 44. This strong efficacy in hard-to-treat patients boosts confidence in the drug's approvability, pushing the stock up 27%.

    This is the core positive catalyst that directly lifted the stock and improved the drug's outlook.

  • Jefferies Upgrade Eases Safety Concerns Jefferies upgraded Abivax to Buy and raised its price target to $158, citing that updated Phase 3 data alleviated concerns over previously reported malignancy cases. The brokerage believes the safety issue is manageable and not a major regulatory hurdle, reinforcing the investment case.

    This analyst action reflects and amplifies the positive data, providing a second driver for the stock's rise.

  • Upsized $800M Offering Extends Cash Runway Abivax priced an upsized $800 million public offering of ADSs at $125 per share, extending its cash runway into Q2 2029. The funds will support commercialization of obefazimod and clinical development, removing near-term financing risk and enabling the company to execute its strategy.

    This capital raise strengthens the balance sheet and supports future growth, a key positive for the stock.

  • Schall Law Firm Investigation Adds Regulatory Overhang The Schall Law Firm is investigating Abivax for potential securities law violations related to undisclosed malignancy cases in the obefazimod trial. This legal scrutiny could lead to fines or reputational damage, weighing on the stock, though the recent positive data may mitigate the impact.

    This is a negative factor that could pressure the stock, providing a balanced view of risks.

Latest
▲3▼1

Abivax Soars on Strong Phase 3 Data, Analyst Upgrade, and $800M Raise

  • Positive Phase 3 Data Drives Stock Surge Abivax reported positive Phase 3 ABTECT Maintenance Part 2 results for obefazimod in refractory ulcerative colitis, showing 37.2% clinical remission and 34.5% endoscopic remission at Week 44. This strong efficacy in hard-to-treat patients boosts confidence in the drug's approvability, pushing the stock up 27%.

    This is the core positive catalyst that directly lifted the stock and improved the drug's outlook.

  • Jefferies Upgrade Eases Safety Concerns Jefferies upgraded Abivax to Buy and raised its price target to $158, citing that updated Phase 3 data alleviated concerns over previously reported malignancy cases. The brokerage believes the safety issue is manageable and not a major regulatory hurdle, reinforcing the investment case.

    This analyst action reflects and amplifies the positive data, providing a second driver for the stock's rise.

  • Upsized $800M Offering Extends Cash Runway Abivax priced an upsized $800 million public offering of ADSs at $125 per share, extending its cash runway into Q2 2029. The funds will support commercialization of obefazimod and clinical development, removing near-term financing risk and enabling the company to execute its strategy.

    This capital raise strengthens the balance sheet and supports future growth, a key positive for the stock.

  • Schall Law Firm Investigation Adds Regulatory Overhang The Schall Law Firm is investigating Abivax for potential securities law violations related to undisclosed malignancy cases in the obefazimod trial. This legal scrutiny could lead to fines or reputational damage, weighing on the stock, though the recent positive data may mitigate the impact.

    This is a negative factor that could pressure the stock, providing a balanced view of risks.

Abcellera Biologics Inc (ABCL)

Q3 2026
▲2▼1

AbCellera's hot-flash drug success and Jazz deal offset weak Q2

  • Jazz partnership brings $56M upfront and up to $792M per program AbCellera signed a deal with Jazz Pharmaceuticals for two antibody programs for solid tumors, receiving $56 million upfront and potentially $792 million per program in milestones plus royalties. This validates its technology and adds non-dilutive cash, supporting the stock.

    This is a new partnership that directly boosts AbCellera's cash and validates its platform, driving positive sentiment.

  • Q2 loss widens to $55M as revenue falls to $4M AbCellera reported a wider net loss of $55 million and revenue dropped to $4 million from $17 million a year ago. The company also missed its internal goal of moving another program into IND-enabling activities, raising concerns about execution.

    This is a new financial report showing deteriorating results, which weighs on the stock price.

  • ABCL635 Phase 2 success sends stock up over 30% AbCellera's hot-flash drug ABCL635 met primary endpoints in a Phase 2 trial, reducing symptoms by 83% versus 33% for placebo with no serious side effects. The stock surged over 30%, as the drug could be a non-hormonal blockbuster.

    This is a major clinical win that directly caused a large stock jump and improves the company's pipeline prospects.

July 2026
▲2▼1

AbCellera's hot-flash drug success and Jazz deal offset weak Q2

  • Jazz partnership brings $56M upfront and up to $792M per program AbCellera signed a deal with Jazz Pharmaceuticals for two antibody programs for solid tumors, receiving $56 million upfront and potentially $792 million per program in milestones plus royalties. This validates its technology and adds non-dilutive cash, supporting the stock.

    This is a new partnership that directly boosts AbCellera's cash and validates its platform, driving positive sentiment.

  • Q2 loss widens to $55M as revenue falls to $4M AbCellera reported a wider net loss of $55 million and revenue dropped to $4 million from $17 million a year ago. The company also missed its internal goal of moving another program into IND-enabling activities, raising concerns about execution.

    This is a new financial report showing deteriorating results, which weighs on the stock price.

  • ABCL635 Phase 2 success sends stock up over 30% AbCellera's hot-flash drug ABCL635 met primary endpoints in a Phase 2 trial, reducing symptoms by 83% versus 33% for placebo with no serious side effects. The stock surged over 30%, as the drug could be a non-hormonal blockbuster.

    This is a major clinical win that directly caused a large stock jump and improves the company's pipeline prospects.

Latest
▲2▼1

AbCellera's hot-flash drug success and Jazz deal offset weak Q2

  • Jazz partnership brings $56M upfront and up to $792M per program AbCellera signed a deal with Jazz Pharmaceuticals for two antibody programs for solid tumors, receiving $56 million upfront and potentially $792 million per program in milestones plus royalties. This validates its technology and adds non-dilutive cash, supporting the stock.

    This is a new partnership that directly boosts AbCellera's cash and validates its platform, driving positive sentiment.

  • Q2 loss widens to $55M as revenue falls to $4M AbCellera reported a wider net loss of $55 million and revenue dropped to $4 million from $17 million a year ago. The company also missed its internal goal of moving another program into IND-enabling activities, raising concerns about execution.

    This is a new financial report showing deteriorating results, which weighs on the stock price.

  • ABCL635 Phase 2 success sends stock up over 30% AbCellera's hot-flash drug ABCL635 met primary endpoints in a Phase 2 trial, reducing symptoms by 83% versus 33% for placebo with no serious side effects. The stock surged over 30%, as the drug could be a non-hormonal blockbuster.

    This is a major clinical win that directly caused a large stock jump and improves the company's pipeline prospects.

© 2026 MarketIVWhy